Abstract Number: 3019 • 2016 ACR/ARHP Annual Meeting
Sputum Antibodies to Individual Citrullinated Protein/Peptide Antigens Are Elevated in Subjects at-Risk of Future RA and Subjects with Established Disease
Background/Purpose: Multiple studies demonstrate that ACPAs are elevated in the serum years prior to the onset of seropositive RA during a preclinical period of autoimmunity.…Abstract Number: 3020 • 2016 ACR/ARHP Annual Meeting
Citrullination of Inhibitor of DNA Binding-1 at Specific Locations Leads to Autoantigenicity in Rheumatoid Arthritis
Background/Purpose: Inhibitor of DNA binding-1 (Id1) is a nuclear transcription factor that regulates cell growth and differentiation via selective binding and sequestering of other transcription…Abstract Number: 3021 • 2016 ACR/ARHP Annual Meeting
Frequency of Arthralgia, Seropositivity, and Seropositive Arthralgia and Their Association with Development of Rheumatoid Arthritis in a Cohort of Indigenous North Americans with or without a First Degree Relative with Rheumatoid Arthritis
Background/Purpose: Anti-citrullinated peptide antibodies and/or rheumatoid factor (RF) in the setting of arthralgia (“seropositive arthralgia”) has been associated with a high risk of development of…Abstract Number: 3022 • 2016 ACR/ARHP Annual Meeting
Autoantibodies to Peptidylarginine Deiminase 2 Protect Against Radiographic Progression in Patients with Rheumatoid Arthritis
Background/Purpose: The mechanisms that drive clinical heterogeneity and outcomes in patients with rheumatoid arthritis (RA) are poorly understood, but precise biomarkers may identify clinically unique…Abstract Number: 3023 • 2016 ACR/ARHP Annual Meeting
Lipid Profile and Effect of Statin Treatment in Pooled Phase 2 and Phase 3 Baricitinib Studies
Background/Purpose: In patients with active RA an increase in lipid analytes has been observed after treatment with janus kinase inhibitors and other disease-modifying antirheumatic drugs.1…Abstract Number: 3024 • 2016 ACR/ARHP Annual Meeting
Major Adverse Cardiovascular Events: Risk Factors in Patients with RA Treated with Tofacitinib
Background/Purpose: RA patients (pts) are at increased risk of myocardial infarction (MI) and stroke that cannot be completely explained by traditional cardiovascular (CV) risk factors.…Abstract Number: 3025 • 2016 ACR/ARHP Annual Meeting
The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies
Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that showed rapid and sustained improvements of signs and symptoms of active rheumatoid…Abstract Number: 3026 • 2016 ACR/ARHP Annual Meeting
The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study
Background/Purpose: Current therapy for rheumatoid arthritis (RA) often leads to excessive immunosuppression induced by glucocorticoids and DMARDs. Low-dose Interleukin 2 (IL-2) has been showed to induce…Abstract Number: 3027 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib
Background/Purpose: Compared to the general population, RA patients (pts) have an increased risk of herpes zoster (HZ) due to their disease and various DMARD therapies…Abstract Number: 3028 • 2016 ACR/ARHP Annual Meeting
A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA
Background/Purpose: The development of clinical signs and symptoms of seropositive rheumatoid arthritis (RA) is often preceded by a phase of systemic autoimmunity. This offers a…Abstract Number: 3029 • 2016 ACR/ARHP Annual Meeting
Ultrasonography of Major Salivary Glands in Patients Suspected with Primary Sjögren’s Syndrome: Comparison with Salivary Gland Biopsy and Classification Criteria
Background/Purpose: Ultrasonography of major salivary glands (sUS) is applied in the diagnostic work-up of primary Sjögren's syndrome (pSS). This study aims to assess (i) the…Abstract Number: 3030 • 2016 ACR/ARHP Annual Meeting
Evidence of Inflammasome Activation in the Peripheral Blood and Salivary Gland Tissues of Primary Sjögren’s Syndrome Patients: Correlation with Clinical Indices of Severe Disease and Lymphoma Development
Background/Purpose: Inflammasomes are intracellular multiprotein complexes that sense pathogenic microorganisms, as well as danger signals released following tissue injury. Such activation of inflammasome leads to…Abstract Number: 3031 • 2016 ACR/ARHP Annual Meeting
Rethinking Primary Sjögren’s Syndrome: Stratification By Clinical Phenotypes to Improve Understanding of Disease Pathogenesis, Trial Design, Clinical Management and Prospective Health Gains?
Background/Purpose: Primary SjšgrenÕs Syndrome (pSS) is a chronic autoimmune rheumatic disease causing a wide-range of symptoms including dryness, pain and fatigue. Individual patient experiences of…Abstract Number: 3032 • 2016 ACR/ARHP Annual Meeting
Abnormalities in the Biological or Haematological Domain of the Essdai Predict an Increase in Systemic Disease Activity the Year after: 5-Year Data from the Prospective Multicenter Assess Cohort
Background/Purpose: Very limited data is available regarding predictors of systemic disease activity in primary Sjögren’s syndrome. The ESSDAI, the international systemic disease activity score of…Abstract Number: 3033 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Single Dose VAY736 (anti-BAFF-R mAb) in Patients with Primary Sjögren’s Syndrome (pSS)
Safety and efficacy of single dose VAY736 (anti-BAFFR mAb) in patients with primary Sjögren’s syndrome (pSS) T Dörner1, M Posch2, F. Wagner2, A Hüser2, T…
ACR Meeting Abstracts